Despite the profitability miss, FY 23/24 guidance unchanged
09/02/24 -"CZM’s Q1 profitability fell short of expectations. Growth was once again led by Microsurgery, while Ophthalmology ended on a flat note. As expected, profitability was under pressure. Nonetheless, FY ..."
Pages
63
Language
English
Published on
09/02/24
You may also be interested by these reports :
17/11/26
Getinge delivered a mixed Q3 26, with sales marginally below consensus but adjusted EBITA well ahead. ACT drove a sharp margin step-up, even before ...
13/11/26
DiaSorin’s Q3 performance exceeded expectations, with revenue acceleration supported by all segments and improved profitability. Full-year guidance ...
13/11/26
Coloplast reported weak Q4 FY26 numbers: revenue beat consensus slightly (+1.1%), but adjusted EBIT missed sharply (-8.4%). More importantly, the new ...
12/11/26
Sonova’s H1 results exceeded expectations. The Hearing Instruments segment drove sales growth, partly offset by weakness in Cochlear Implants. ...